Farxiga Drug Patent Profile

Which patents cover Farxiga, and what generic alternatives are available?

Farxiga is a drug marketed by Astrazeneca Ab and is included in one NDA. There are seventeen patents protecting this drug and one Paragraph IV challenge.

This drug has four hundred and thirty-seven patent family members in fifty-three countries.

The generic ingredient in FARXIGA is dapagliflozin. There is one drug master file entry for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the dapagliflozin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Farxiga

A generic version of Farxiga was approved as dapagliflozin by AIZANT on April 6^th, 2026.

Summary for Farxiga

International Patents:	437
US Patents:	17
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	50
Patent Applications:	1
Drug Prices:	Drug price information for Farxiga
Drug Sales Revenues:	Drug sales revenues for Farxiga
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for Farxiga
What excipients (inactive ingredients) are in Farxiga?	Farxiga excipients list
DailyMed Link:	Farxiga at DailyMed

See drug prices for Farxiga

See drug sales revenues for Farxiga

Recent Clinical Trials for Farxiga

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	PHASE2
UnitedHealthcare	PHASE2
The University of Hong Kong	Phase 2

See all Farxiga clinical trials

Pharmacology for Farxiga

Drug Class	Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	Sodium-Glucose Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for FARXIGA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FARXIGA	Tablets	dapagliflozin	5 mg and 10 mg	202293	20	2018-01-08

US Patents and Regulatory Information for Farxiga

Farxiga is protected by seventeen US patents and four FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	AB	RX	Yes	Yes	12,213,988*PED				Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	AB	RX	Yes	Yes	11,826,376*PED				Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	AB	RX	Yes	Yes
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	AB	RX	Yes	Yes	11,903,955*PED				Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014	AB	RX	Yes	No	8,221,786*PED				Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	AB	RX	Yes	Yes	7,851,502*PED				Y

Expired US Patents for Farxiga

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014	9,198,925
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	7,563,871
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	6,414,126
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014	6,667,061
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014	7,741,269
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	6,495,164

EU/EMA Drug Approvals for Farxiga

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AstraZeneca AB	Forxiga	dapagliflozin	EMEA/H/C/002322Type 2 diabetes mellitusForxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureForxiga is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseForxiga is indicated in adults for the treatment of chronic kidney disease.	Authorised	no	no	no	2012-11-11
AstraZeneca AB	Edistride	dapagliflozin	EMEA/H/C/004161Type 2 diabetes mellitusEdistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureEdistride is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseEdistride is indicated in adults for the treatment of chronic kidney disease.	Authorised	no	no	no	2015-11-09
Viatris Limited	Dapagliflozin Viatris	dapagliflozin	EMEA/H/C/006006Type 2 diabetes mellitusDapagliflozin Viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance.- in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureDapagliflozin Viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.Chronic kidney diseaseDapagliflozin Viatris is indicated in adults for the treatment of chronic kidney disease.	Authorised	yes	no	no	2023-03-24

International Patents for Farxiga

When does loss-of-exclusivity occur for Farxiga?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Chile

Denmark

European Patent Office

Japan

Mexico

Serbia

Slovenia

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering Farxiga around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	026024	COMPUESTOS INHIBIDORES SGLT2 DE GLUCOSIDOS DE C-ARILO Y METODO, LAS COMPOSICIONES FARAMCEUTICAS QUE LOS CONTIENEN Y LOS INTERMEDIARIOS DE SINTESIS DEDICHOS COMPUESTOS
Argentina	040032	C-ARIL-GLUCOSIDOS COMO INHIBIDORES DE SGLT2 Y METODO
Austria	295848
Austria	353334
Australia	2003237886	C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD
Australia	781009

Supplementary Protection Certificates for Farxiga

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506211	C300585	Netherlands		PRODUCT NAME: DAPAGLIFLOZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/12/795/001-010 20121112
1506211	PA2013008	Lithuania		PRODUCT NAME: DAPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/12/795/001 - EU/1/12/795/010 20121112
1506211	122013000033	Germany		PRODUCT NAME: DAPAGLIFLOZIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/795/001-010 20121112
1506211	C20130006 00074	Estonia		PRODUCT NAME: DAPAGLIFLOZIN;REG NO/DATE: K(2012)8378 12.11.2012
1506211	92182	Luxembourg		PRODUCT NAME: DAPAGLIFLOZINE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
1506211	2013/013	Ireland		PRODUCT NAME: DAPAGLIFLOZIN AND PHARACEUTICALLY ACCEPTABLE SALTS THREOF; REGISTRATION NO/DATE: EU/1/12/795/001-010 20121112

FARXIGA Market Dynamics, Patent Estate, Generic Risk, and Financial Trajectory

Last updated: August 10, 2026

FARXIGA, AstraZeneca's dapagliflozin product, has shifted from a type 2 diabetes drug to a broad cardiorenal franchise. Its commercial growth has been driven primarily by heart-failure and chronic-kidney-disease use, not by diabetes alone. Revenue has increased from roughly $1.9 billion in 2020 to approximately $7 billion in 2024, while patent protection remains relevant through method-of-use and formulation claims even after the earliest compound patent expired.

What is FARXIGA and how does it work?

FARXIGA is the U.S. brand name for dapagliflozin, an oral sodium-glucose cotransporter 2, or SGLT2, inhibitor. AstraZeneca markets the drug globally under the names FARXIGA and Forxiga.

Dapagliflozin reduces renal glucose reabsorption by inhibiting SGLT2 in the proximal renal tubule. The resulting urinary glucose excretion lowers blood glucose and produces additional effects relevant to heart failure and kidney disease, including natriuresis and reduced intraglomerular pressure.

The current product has four principal commercial indications:

Indication	U.S. regulatory milestone	Commercial importance
Type 2 diabetes mellitus	FDA approval in 2014	Original market
Heart failure with reduced ejection fraction	FDA expansion in 2020	Established a major cardiovascular market
Heart failure across the ejection-fraction spectrum	FDA expansion in 2022	Expanded addressable heart-failure population
Chronic kidney disease at risk of progression	FDA approval in 2021	Major growth driver outside diabetes

The FDA has not approved FARXIGA for type 1 diabetes in the United States. The drug is also not an insulin replacement.

How has FARXIGA revenue changed over time?

FARXIGA's financial trajectory has been one of AstraZeneca's strongest post-2020 growth stories. The product benefited from guideline adoption, broader cardiology prescribing, chronic-kidney-disease screening, and increasing use by physicians outside endocrinology.

FARXIGA reported sales trajectory

Fiscal year	Approximate global revenue	Primary growth driver
2019	$1.5 billion	Diabetes market
2020	$1.9 billion	Initial heart-failure adoption
2021	$3.0 billion	Heart failure and broader global uptake
2022	$4.4 billion	Heart failure plus CKD
2023	$5.7 billion	Cardiorenal expansion
2024	Approximately $7 billion	Continued CKD and heart-failure penetration

Sources include AstraZeneca annual reports and full-year earnings disclosures.[1-5]

The revenue profile indicates that FARXIGA is no longer economically dependent on the diabetes market. Cardiovascular and renal indications support prescribing even when glucose lowering is not the primary treatment objective.

AstraZeneca's reported product sales are affected by foreign-exchange movements, geographic pricing, government rebates, managed-care discounts, and collaboration accounting. The figures therefore indicate commercial scale rather than U.S. net sales alone.

What markets drive FARXIGA growth?

Chronic kidney disease

CKD has become one of the most important growth markets for FARXIGA. The DAPA-CKD trial showed a reduction in the risk of sustained kidney-function decline, kidney failure, and cardiovascular or renal death in patients with CKD, including patients without diabetes.[6]

The commercial opportunity is large because CKD is frequently underdiagnosed and is associated with high hospitalization and dialysis costs. SGLT2 inhibitors are increasingly used earlier in the treatment pathway, particularly in patients with albuminuria or elevated renal risk.

FARXIGA competes with Jardiance, which is marketed by Boehringer Ingelheim and Eli Lilly. Jardiance has also developed a broad heart-failure and CKD profile, making clinical guideline positioning and payer formulary access central competitive variables.

Heart failure

Heart failure has changed the prescribing base for dapagliflozin. DAPA-HF supported use in heart failure with reduced ejection fraction, while DELIVER supported treatment across a broader ejection-fraction population.[7,8]

The drug does not require insulin titration and has a relatively simple once-daily oral regimen. These attributes support use by cardiologists, nephrologists, and primary-care physicians.

Type 2 diabetes

Diabetes remains a large underlying market but is no longer the sole source of growth. FARXIGA faces competition from:

• Jardiance, or empagliflozin
• Invokana, or canagliflozin
• GLP-1 products such as Ozempic, Rybelsus, Trulicity, and Mounjaro
• Combination regimens involving metformin, insulin, and other oral agents

GLP-1 therapies compete for patients seeking weight loss and glucose control. SGLT2 inhibitors retain a differentiated position where heart-failure or kidney-risk reduction is the primary treatment objective.

How does FARXIGA compare with Jardiance?

Category	FARXIGA	Jardiance
Active ingredient	Dapagliflozin	Empagliflozin
Manufacturer	AstraZeneca	Boehringer Ingelheim and Eli Lilly
Drug class	SGLT2 inhibitor	SGLT2 inhibitor
Diabetes approval	2014	2014
Heart-failure positioning	Broad heart-failure label	Broad heart-failure label
CKD positioning	Major approved indication	Major approved indication
Core differentiation	Early cardiorenal expansion and strong CKD positioning	Strong cardiovascular outcomes and diabetes franchise
Main commercial risk	Generic entry and Jardiance competition	Generic entry and FARXIGA competition

The two products are close commercial substitutes. Their competitive positions depend more on guideline recommendations, trial interpretation, formulary placement, contracting, and prescriber familiarity than on major differences in oral administration.

What patents protect FARXIGA?

FARXIGA's patent estate has evolved from composition-of-matter protection to later method-of-use and formulation protection.

Key U.S. patent categories

Patent category	Representative U.S. patent	Subject matter	Reported expiry position
Core compound	US 6,515,117	C-glucoside compounds, including dapagliflozin chemistry	Expired in 2020
Solid-state or formulation protection	US 9,364,520	Dapagliflozin-related pharmaceutical composition and use claims	Approximately 2028
Later method-of-use protection	US 10,092,541	Cardiorenal treatment methods	Approximately 2030
Additional formulation or use patents	Various later patents	Dosage forms, combinations, and therapeutic use	Expiry varies by patent and jurisdiction

The Orange Book is the controlling U.S. reference for patents listed against approved drug products. Listed patents can change through regulatory updates, patent-term adjustments, pediatric extensions, and litigation outcomes.[9]

The earliest compound patent's expiration did not create an immediate generic market because later patents and ANDA litigation can delay approval or commercial launch. In practice, a generic applicant must address each relevant Orange Book-listed patent through certification and litigation strategy.

When does FARXIGA lose exclusivity?

FARXIGA's regulatory exclusivity has already expired. The original five-year new chemical entity exclusivity period ended years ago. The commercial exclusivity question now depends primarily on patents, ANDA litigation, settlements, and the timing of generic approvals.

A simplified U.S. exclusivity timeline is:

Event	Approximate date
FDA approval for type 2 diabetes	2014
NCE exclusivity	Ended in 2019
Core compound patent expiry	2020
Major heart-failure expansion	2020
CKD approval	2021
Broader heart-failure expansion	2022
Later method-of-use patent protection	Approximately 2028-2030
Likely meaningful generic pressure	Dependent on ANDA litigation and settlements

The practical loss-of-exclusivity date can differ by indication. A generic may launch for an unprotected use while remaining exposed to infringement claims for protected indications. That creates a potential skinny-label strategy, although the commercial value of such a launch depends on pharmacy substitution, payer practices, prescriber behavior, and the scope of carve-outs.

What is the Orange Book status of FARXIGA?

FARXIGA is an FDA-approved small-molecule drug listed in the Orange Book. It is not a biologic, so biosimilar regulation under the Public Health Service Act does not apply. Generic applicants must file abbreviated new drug applications, or ANDAs, under the Hatch-Waxman framework.

The relevant Orange Book issues include:

1. Whether a patent is listed against the current FARXIGA product and indication set.
2. Whether an ANDA applicant files a Paragraph IV certification.
3. Whether AstraZeneca sues within the statutory period.
4. Whether a 30-month stay delays FDA approval.
5. Whether the generic applicant seeks approval for all indications or uses a label carve-out.
6. Whether a settlement provides a licensed entry date.

The Orange Book does not itself determine whether a patent is valid or infringed. Those issues are resolved through litigation, settlement, or administrative proceedings.

Which companies are challenging FARXIGA patents?

FARXIGA has attracted the expected category of ANDA challenges from generic pharmaceutical manufacturers as the core compound patent has expired and later patents approach their expiry dates. Publicly reported litigation and regulatory records should be reviewed by applicant, patent number, district court, and settlement status because the challenger list and case posture can change.

Typical potential challengers include large generic manufacturers and major Indian generic companies with U.S. ANDA operations. The commercial significance of each challenger depends on whether it has:

• Received tentative or final FDA approval
• Filed a Paragraph IV certification
• Preserved 180-day generic exclusivity
• Reached a settlement with AstraZeneca
• Obtained approval for a full or carved-out label
• Secured manufacturing capacity for commercial launch

A Paragraph IV filing is an assertion that a listed patent is invalid, unenforceable, or not infringed. It is not proof that a generic will launch. AstraZeneca can respond with patent litigation, and the litigation can result in a 30-month approval stay.

What generic entry risks exist for FARXIGA?

The generic-entry risk is significant but likely staged rather than instantaneous.

Scenario 1: Delayed entry after patent litigation

AstraZeneca may defend later patents through litigation and preserve branded sales until the 2028-2030 period. This scenario supports a slower erosion curve and gives AstraZeneca additional time to shift patients toward other products.

Scenario 2: Authorized or licensed generic entry

A settlement may permit a generic launch before the last listed patent expires. The entry date could be confidential or could appear in a public settlement filing. An authorized generic would allow AstraZeneca to retain some economics while reducing the risk of an uncontrolled competitor launch.

Scenario 3: Skinny-label entry

A generic applicant could omit patented heart-failure or CKD indications if the remaining patent claims cover specific uses. This strategy may still create meaningful substitution because prescribers often use generic SGLT2 inhibitors across overlapping clinical populations.

Scenario 4: Multiple-generic launch

Once several ANDA applicants receive approval, price erosion would accelerate. SGLT2 inhibitors are chemically simple oral products, and manufacturing barriers are lower than for biologics, complex injectables, or specialized delivery systems.

The highest-value risk is not necessarily the first generic approval. It is the point at which multiple manufacturers gain approval and payers begin treating dapagliflozin as a commodity product.

What formulation patents protect FARXIGA?

FARXIGA is an oral tablet. Its formulation protection can cover:

• Tablet composition
• Dapagliflozin crystalline or solid-state forms
• Excipients and stability characteristics
• Dosage strengths
• Combination products
• Manufacturing processes
• Pharmaceutical compositions designed for consistent dissolution or bioavailability

Formulation patents generally provide narrower protection than a compound patent. Their value depends on whether a generic can design around the claims while preserving bioequivalence.

Combination products also create a separate IP layer. AstraZeneca has marketed dapagliflozin in combination with metformin, including XIGDUO XR. Combination-product patents may not prevent a generic from entering the single-agent dapagliflozin market.

What manufacturing and intellectual-property barriers affect FARXIGA?

Dapagliflozin is a small-molecule active pharmaceutical ingredient with established synthetic routes. The manufacturing barrier is therefore moderate rather than extreme.

The main barriers are:

• Demonstrating pharmaceutical equivalence and bioequivalence
• Producing the correct crystalline form
• Controlling impurities and residual solvents
• Meeting tablet dissolution specifications
• Establishing reliable API supply
• Resolving formulation and process patents
• Obtaining FDA approval after Paragraph IV litigation
• Building payer access and distribution capacity

The API process may be protected by patents separate from the finished dosage form. A generic manufacturer can often design around process claims, but process changes can increase development time and regulatory cost.

What licensing deals shaped FARXIGA?

FARXIGA originated from the diabetes collaboration between AstraZeneca and Bristol-Myers Squibb. AstraZeneca later acquired Bristol-Myers Squibb's interest in the companies' diabetes alliance, giving AstraZeneca full control of FARXIGA and related diabetes assets.

The transaction strengthened AstraZeneca's long-term control over:

• Global commercialization
• Regulatory strategy
• Patent prosecution and litigation
• Pricing and market access
• Lifecycle expansion into heart failure and CKD

The deal also concentrated commercial and legal risk in AstraZeneca. The company now captures the upside from cardiorenal growth but carries the cost of defending the franchise against generic and branded competition.

What litigation and settlement issues affect FARXIGA?

The central legal issues are likely to involve:

1. Validity of later method-of-use patents.
2. Infringement by generic labels and promotional conduct.
3. Whether a generic label carve-out is sufficient.
4. Patent-term calculations and pediatric extensions.
5. Settlement dates and possible 180-day exclusivity.
6. Antitrust scrutiny of delayed-entry agreements.

A patent settlement can preserve substantial value even without full trial victory if it provides a defined generic entry date. Conversely, an adverse validity ruling against a later patent could expose the franchise to earlier-than-expected erosion.

What is the FDA regulatory status of FARXIGA?

FARXIGA has full FDA approval for multiple adult cardiorenal and diabetes uses. Its regulatory position is stronger than that of an early-stage product because the label is supported by a large clinical-trial package and long-term postmarketing experience.

The principal regulatory risks are commercial rather than approval-related:

• Safety-label changes
• Class-wide SGLT2 warnings
• Renal-function restrictions
• Reimbursement limits
• Prior authorization
• Shifts in diabetes and heart-failure guidelines

Important class risks include ketoacidosis, genital mycotic infections, volume depletion, and rare serious infections. These risks are reflected in FDA labeling and can influence prescribing and payer policies.[10]

How strong is the FARXIGA patent estate?

The FARXIGA patent estate is commercially strong but no longer compound-patent strong.

Strength factor	Assessment
Core molecule protection	Expired
Regulatory exclusivity	Expired
Cardiorenal clinical differentiation	Strong
Method-of-use protection	Material through the late 2020s, subject to validity and litigation
Formulation protection	Relevant but generally narrower
Manufacturing complexity	Moderate
Generic substitution risk	High after final patent barriers fall
Franchise resilience	Strong because of multiple indications and prescriber types

The most valuable asset is now the combination of clinical evidence, guideline inclusion, payer coverage, and later-use patents. That combination can delay erosion, but it cannot provide the same long-term barrier as an unexpired composition patent.

How does FARXIGA affect AstraZeneca's revenue exposure?

FARXIGA has become a major contributor to AstraZeneca's growth portfolio. At approximately $7 billion in annual sales, it represents a material share of group revenue and an even larger share of growth in selected reporting periods.

Revenue exposure is concentrated in:

• U.S. heart-failure and CKD prescribing
• European and Japanese cardiorenal markets
• Government reimbursement
• SGLT2 class utilization
• Timing of U.S. generic entry
• Competitive performance against Jardiance

A rapid U.S. generic launch would create a disproportionate earnings effect because the United States carries higher branded pricing than many international markets. A later, staged launch would allow AstraZeneca to retain revenue while expanding other growth products.

What generic launch scenarios should investors monitor?

The most important indicators are:

• New Paragraph IV ANDA litigation filings
• FDA tentative approvals
• Final approvals for dapagliflozin tablets
• Court rulings on Orange Book-listed patents
• Public settlement agreements
• Authorized-generic announcements
• Changes to the FARXIGA Orange Book listing
• Payer formulary decisions
• Quarterly U.S. prescription and market-share data

The base commercial risk is a gradual erosion after later-use patents expire or are invalidated. A sharper decline would occur if several generic manufacturers launch simultaneously or if a court removes a key late-expiring patent.

Key Takeaways

• FARXIGA is dapagliflozin, an SGLT2 inhibitor marketed by AstraZeneca.
• The product has expanded from type 2 diabetes into heart failure and chronic kidney disease.
• Global revenue increased from roughly $1.9 billion in 2020 to approximately $7 billion in 2024.
• The original compound patent expired around 2020, but later method-of-use and formulation patents may extend practical protection into the late 2020s or around 2030.
• FARXIGA is subject to ANDA-based generic risk, not biosimilar risk.
• Jardiance is the principal branded competitor.
• The commercial franchise remains strong because cardiorenal prescribing supports use beyond glucose control.
• The major valuation issue is the timing and structure of U.S. generic entry.
• A skinny-label, licensed, or staggered generic launch would produce less severe erosion than a simultaneous multi-generic launch.
• AstraZeneca's clinical evidence and guideline position provide commercial resilience after patent expiry, but they do not prevent eventual price erosion.

FAQs

Does FARXIGA have biosimilar competition?

No. FARXIGA is a small-molecule drug, so competitors file ANDAs as generic drugs rather than biosimilar applications.

Can a generic dapagliflozin product launch before all FARXIGA patents expire?

Yes. A generic may launch after prevailing in Paragraph IV litigation, reaching a settlement, obtaining a license, or carving patented indications out of its label.

Is FARXIGA or Jardiance more commercially exposed to generic entry?

Both face substantial long-term generic risk because they are oral small-molecule SGLT2 inhibitors. Relative exposure depends on each product's remaining patents, litigation outcomes, and settlement terms.

Do FARXIGA combination products have separate patent protection?

Yes. Products combining dapagliflozin with metformin or other active ingredients can have separate formulation, composition, or use patents. Those patents do not necessarily block generic single-agent dapagliflozin.

What is the largest future market for FARXIGA?

Chronic kidney disease and heart failure are the principal expansion markets. Their value comes from treatment of patients who may not need dapagliflozin primarily for glucose lowering.

References

1. AstraZeneca. (2020). Annual report and Form 20-F 2020. AstraZeneca PLC.
2. AstraZeneca. (2021). Annual report and Form 20-F 2021. AstraZeneca PLC.
3. AstraZeneca. (2022). Annual report and Form 20-F 2022. AstraZeneca PLC.
4. AstraZeneca. (2023). Annual report and Form 20-F 2023. AstraZeneca PLC.
5. AstraZeneca. (2024). Full-year and fourth-quarter 2024 results. AstraZeneca PLC.
6. Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383, 1436-1446.
7. McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, 1995-2008.
8. Solomon, S. D., McMurray, J. J. V., Claggett, B., et al. (2022). Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine, 387, 1089-1098.
9. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
10. U.S. Food and Drug Administration. (2024). FARXIGA prescribing information. AstraZeneca Pharmaceuticals LP.

DrugChatter Q&A for FARXIGA

Has farxiga lost exclusivtiy patent in 2026?
Farxiga 10 mg?
Cost of farxiga in usa?
Farxiga generic approval date?
Date expiration brevet farxiga?